ArticleOncotarget2015

Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.

Judith Jakoby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.